Erdheim-Chester disease: atypical presentation of a rare disease

BMJ Case Rep. 2017 Oct 11:2017:bcr2017220827. doi: 10.1136/bcr-2017-220827.

Abstract

We report the clinical case of an adult patient referred to our hospital because of trismus due to a tumour in the right infratemporal and pterygomaxillary fossa. He referred hyporexia, weight loss and right trigeminal neuralgia. On physical examination, he had trismus and diplopia. On neuroimaging, the tumour invaded the central nervous system affecting the right temporal lobe and orbit, and the sellar region. Tumour biopsy revealed foamy histiocytes and isolated giant multinuclear cells immunoreactive to CD68 and negative to CD1a and S100. A diagnosis of Erdheim-Chester disease was made. Non-evidence of large bone involvement was found in neither plain radiographs nor Technetium 99 m bone scintigraphy. BRAFV600E mutation analysis was negative. Because of raised intracranial pressure, a debulking surgery of the intracranial histiocytic process was performed. The patient improved his symptoms and remains clinically stable after 12 months of treatment with pegylated interferon-α-2a 180 µg/weekly.

Keywords: haematology (incl bloodtransfusion); neurology.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Cytoreduction Surgical Procedures / methods*
  • DNA Mutational Analysis
  • Diplopia / etiology
  • Erdheim-Chester Disease / diagnosis*
  • Erdheim-Chester Disease / physiopathology
  • Erdheim-Chester Disease / therapy
  • Histiocytes / pathology*
  • Humans
  • Interferon-alpha / therapeutic use*
  • Male
  • Neuroimaging
  • Polyethylene Glycols / therapeutic use*
  • Rare Diseases
  • Recombinant Proteins / therapeutic use
  • Tomography, X-Ray Computed*
  • Treatment Outcome
  • Trismus / etiology

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2a